ARCHIVES

Iniparib Doesn’t Meet Survival, PFS Endpoints In Phase III Trial in Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 34 No. 2 | February 25, 2011

Download PDF Visit The Full Archive

Related Articles

NCI, Groups Disagree Over Recovery Of Funds In Cases of Scientific Fraud

October 7, 1994

Avastin Vote Puts Focus On FDA Criteria In First-Line Metastatic Breast Cancer: Is PFS Good Enough?

December 14, 2007

Also in this 8-page issue: Despite press reports, no settlement date yet for Bristol-Myers pact with federal prosecutors.

June 10, 2005

FDA, ASCO Meet to Review Drug Approval Endpoints

April 25, 2003

Centers Program Needs ‘Innovative Additions’ Such as SPORE Grants

September 20, 1991

ASCO Advises KRAS Testing In Patients With Metastatic Colorectal Cancer

January 30, 2009